[In vitro antitumor immune response induced by fusion of dendritic cells and Ewing's sarcoma cells].
OBJECTIVE
Human Ewing sarcoma A673 cells and human peripheral blood-derived DCs were fused to induce an antitumor activity against human EW.


METHODS
EW A673 cells and human peripheral blood-derived DCs were fused with polyethylene glycol (PEG).


RESULTS
Mature DCs with highly expressed surface markers (CD80, CD86, CD83 and HLA-DR) were generated in vitro and flow cytometry. It showed that the highest fusion efficiency was 23.01%. T cell proliferation assay indicated that the novel dendritomas in fused DCs/A673 cells were the most potent in activation of autologous T cell proliferation. The IFN-gamma assay showed that The IFN-gamma secretion by CTLs activated by the novel dendritomas increased more than by other stimulators. CTL assay demonstrated that the novel dendritomas induced A673 cell-specific cytotoxic responses to lyse the A673 cells in the context of MHC class I.


CONCLUSIONS
The data indicates that fusion of tumor cells with DCs is an attractive strategy to induce tumor rejection.
Tang
Shun
S
Department of Orthopaedic Oncology, Peking University People's Hospital, Beijing 100044, China. tangshun78@sohu.com
Guo
Wei
W
Guo
Yi
Y
Qu
Hua-yi
HY
Li
Da-sen
DS
D019496:Cancer Vaccines / Q000276:immunology*; D002459:Cell Fusion; D003602:Cytotoxicity, Immunologic; D003713:Dendritic Cells / Q000276:immunology*; D006801:Humans; D066298:In Vitro Techniques; D012512:Sarcoma, Ewing / Q000276:immunology* / Q000473:pathology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
D019496:Cancer Vaccines